Drugs / Secukinumab
Secukinumab
also known as
AIN457 · COSENTYX · AIN457A · CMAB015 · Cosentyx TM · Secukinumab (AIN457) 150 mg s.c.
Monoclonal antibody targets IL17A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 13 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (11) | US (FDA) | COSENTYX | — | 2016-01-15 – 2026-04-17 | fda.gov ↗ |
| Approved | US (FDA) | COSENTYX | — | 2015-01-21 | fda.gov ↗ |
| Approved | EU (EMA) | Cosentyx | — | 2015-01-14 | europa.eu ↗ |
Trials 175 · started per year
today
EU approved 2015
US approved 2015
1
1
4
8
10
12
10
10
7
14
18
11
7
9
15
9
7
6
6
5
5
20062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04414605 | Jun 2020 → Dec 2021 | psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 0 | NCT03099980 | Jul 2016 → Dec 2018 | hidradenitis suppurativa | Tufts Medical Center | Completed | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT07237594 | Mar 2026 → Jun 2027 expected | metastatic melanoma | Duke University | Recruiting | No outcome recorded |
| Phase 1 | NCT07254325 | Dec 2025 → Jun 2026 overdue | psoriasis | Taizhou Mabtech Pharmaceutical Co.,Ltd | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06751238 | Sep 2025 → Nov 2032 expected | psoriasis-related juvenile idiopathic arthritis | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06130540 | Mar 2024 → Mar 2025 | polymyalgia rheumatica, temporal arteritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05734482 | Feb → Jul 2023 | psoriasis | Taizhou Mabtech Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05522517 | Aug → Nov 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04967950 | Jul 2021 → Oct 2022 | psoriatic arthritis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03342573 | Apr 2018 → Jan 2022 | adult onset pityriasis rubra pilaris | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02607774 | Dec 2015 → Dec 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01539213 | Feb 2012 → Jan 2013 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT04298320 | Mar 2020 → Feb 2022 | colorectal cancer | Yanqiao Zhang | Unknown | No outcome recorded |
| Phase 1/2 | NCT03079531 | Jun 2017 → Jan 2019 | rosacea | Anne Chang | Completed | No outcome recorded |
| Phase 1/2 | NCT02733094 | Apr 2016 → Sep 2019 | pyoderma gangrenosum | Technical University of Munich | Completed | No outcome recorded |
| Phase 1/2 | NCT00920933 | Jan → Nov 2009 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00669916 | Feb → Nov 2007 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00669942 | Dec 2005 → Nov 2008 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 240 trials | ||||||
| Phase 2 | NCT07477795 | Apr 2026 → Oct 2029 expected | Takayasu arteritis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07138898 | Dec 2025 → Jan 2028 expected | rheumatic disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT04274166 | May → Dec 2021 | pyoderma gangrenosum | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2 | NCT03651518 | Oct 2020 → Nov 2025 | autoimmune disease, inflammatory disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT04300296 | Jul 2020 → Nov 2021 | lichen planus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04403243 | May → Jul 2020 | COVID-19 | Lomonosov Moscow State University Medical Research and Educational Center | Completed | No outcome recorded |
| Phase 2 | NCT03866317 | Sep 2019 → Jun 2021 | discoid lupus erythematosus | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT03791060 | Apr 2019 → Jan 2021 | necrobiosis lipoidica | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03765788 | Jan 2019 → Jun 2021 | temporal arteritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03568136 | Sep 2018 → May 2020 | atopic eczema | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03344640 | Dec 2017 → Aug 2019 | disease of the tendon | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03131570 | May 2017 → Jan 2020 | psoriasis | James G. Krueger, MD, PhD | Completed | No outcome recorded |
| Phase 2 | NCT03041038 | Dec 2016 → Aug 2020 | Netherton syndrome, congenital non-bullous ichthyosiform erythroderma, epidermolytic ichthyosis, lamellar ichthyosis | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT02854163 | Oct 2016 → Sep 2019 | psoriatic arthritis | University of Liverpool | Completed | No outcome recorded |
| Phase 2 | NCT02594098 | Nov 2015 → Jan 2018 | atopic eczema | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT02599129 | Nov 2015 → Nov 2016 | alopecia areata | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 2 | NCT02483234 | May 2015 → Jun 2018 | psoriasis, psoriatic arthritis | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 2 | NCT02044848 | Feb → Sep 2014 | type 1 diabetes mellitus | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01874340 | Jun 2013 → Apr 2014 | multiple sclerosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01478360 | Mar 2012 → Nov 2014 | asthma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01433250 | Feb 2012 → Jun 2014 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01537432 | Jan 2012 → Dec 2014 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01359943 | Oct 2011 → Dec 2013 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01426789 | Aug 2011 → Feb 2014 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01364389 | Feb 2011 → Jan 2013 | inflammatory disease, polymyalgia rheumatica | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01250171 | Nov 2010 → Sep 2011 | dry eye syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01169844 | Jun 2010 → Nov 2012 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01132612 | May 2010 → Oct 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01109940 | Apr 2010 → Dec 2012 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01071252 | Mar 2010 → Feb 2011 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01051817 | Dec 2009 → Apr 2012 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01009281 | Oct 2009 → Aug 2010 | Crohn disease | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00941031 | Jul 2009 → Dec 2010 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00928512 | Jul 2009 → Mar 2011 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00809159 | Mar 2009 → May 2011 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00809614 | Mar 2009 → Dec 2010 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00805480 | Dec 2008 → Sep 2010 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00770965 | Sep 2008 → Sep 2009 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00584740 | Aug 2008 → Aug 2010 | Crohn disease | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00685399 | Jun 2008 → Sep 2013 | uveitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 381 trials | ||||||
| Phase 3 | NCT06331312 | Jun 2024 → May 2028 expected | polymyalgia rheumatica | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05722522 | Aug 2023 → Oct 2024 | rotator cuff syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT05758415 | Aug 2023 → Oct 2024 | rotator cuff syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT05767034 | Mar 2023 → Sep 2025 | polymyalgia rheumatica | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT05569174 | Dec 2022 → Dec 2024 | disease of the tendon | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT05380453 | Sep 2022 → Feb 2026 | temporal arteritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT05232864 | Aug 2022 → Aug 2023 | lupus nephritis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT05206591 | Aug 2022 → Mar 2028 | spondyloarthropathy | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT04930094 | Oct 2021 → Apr 2025 | temporal arteritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04732117 | Jul 2021 → Apr 2024 | spondyloarthropathy | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04711902 | Jun 2021 → Jun 2022 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04632927 | Dec 2020 → Oct 2024 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04610476 | Oct 2020 → Oct 2024 | psoriatic arthritis, substance withdrawal syndrome | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT04181762 | Jul 2020 → Sep 2023 | lupus nephritis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT04237116 | Feb 2020 → Jun 2021 | NAFLD1, psoriasis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT04209205 | Jan 2020 → May 2022 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04156620 | Dec 2019 → Feb 2022 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03769168 | Jun 2019 → Nov 2024 | enthesitis-related juvenile idiopathic arthritis, psoriasis-related juvenile idiopathic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03906136 | Jun 2019 → Feb 2022 | spondyloarthropathy | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03589885 | Dec 2018 → Nov 2019 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03668613 | Aug 2018 → Sep 2019 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03504852 | Jun 2018 → Sep 2019 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03259074 | Nov 2017 → Nov 2021 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03136861 | Jun 2017 → Feb 2019 | spondyloarthropathy | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03031782 | May 2017 → Oct 2020 | enthesitis-related juvenile idiopathic arthritis, psoriasis-related juvenile idiopathic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02745080 | Apr 2017 → Dec 2019 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03066609 | Feb → Dec 2017 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02748863 | Dec 2016 → Aug 2017 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02896127 | Oct 2016 → May 2018 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02721966 | Oct 2016 → Jun 2019 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02771210 | Aug 2016 → Dec 2019 | enthesitis, psoriatic arthritis, spondyloarthropathy | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02826603 | Jun 2016 → Jul 2018 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02795416 | Jun 2016 → Mar 2017 | psoriasis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT02696031 | Apr 2016 → Jul 2019 | spondyloarthropathy | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02750592 | Mar 2016 → Jul 2017 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02778711 | Jan 2016 → Jun 2017 | allergic contact dermatitis | Tanja Todberg, MD | Unknown | No outcome recorded |
| Phase 3 | NCT02471144 | Sep 2015 → Dec 2018 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02404350 | Aug 2015 → Aug 2017 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02294227 | May 2015 → Feb 2016 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02595970 | May 2015 → Feb 2017 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02159053 | May 2015 → Feb 2016 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02409667 | May 2015 → Mar 2017 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02394561 | Apr 2015 → Jun 2017 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02474082 | Apr 2015 → Jun 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02362789 | Jan 2015 → Jul 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02267135 | Sep 2014 → Dec 2015 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01989468 | Apr 2014 → May 2015 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02559622 | Apr 2014 → Apr 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03358134 | Mar 2014 → Jul 2017 | spondyloarthropathy | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 3 | NCT02074982 | Feb 2014 → Jun 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02008916 | Jan 2014 → Feb 2015 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02008890 | Dec 2013 → Nov 2014 | palmoplantar pustulosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01863732 | Nov 2013 → Mar 2018 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01961609 | Oct 2013 → Jul 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01900782 | Oct 2013 → Jun 2015 | psoriasis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01892436 | Sep 2013 → Jan 2018 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01952015 | Aug 2013 → Mar 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01807520 | Jun 2013 → Jan 2017 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01806597 | Jun 2013 → Nov 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01752634 | Apr 2013 → May 2014 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01649375 | Oct 2012 → Aug 2014 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01636687 | Oct 2012 → Oct 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01770379 | Oct 2012 → May 2015 | rheumatoid arthritis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01640951 | Sep 2012 → May 2017 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01544595 | Jun 2012 → Jun 2017 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01555125 | May 2012 → Oct 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01412944 | Dec 2011 → Apr 2013 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01358175 | Oct 2011 → Dec 2014 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01392326 | Sep 2011 → Oct 2014 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01350804 | Sep 2011 → Feb 2015 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01377012 | Aug 2011 → Sep 2015 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01406938 | Aug 2011 → May 2013 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01358578 | Jun 2011 → Jul 2013 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01365455 | Jun 2011 → Apr 2013 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01327664 | Mar 2011 → May 2014 | uveitis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01103024 | Dec 2010 → Feb 2011 | uveitis | Novartis | Withdrawn | No outcome recorded |
| Phase 3 | NCT01090310 | Aug 2010 → Jul 2011 | uveitis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01095250 | Apr → Oct 2010 | uveitis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01093846 | Mar 2010 → Jan 2011 | uveitis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01032915 | Feb 2010 → Jun 2011 | uveitis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00995709 | Oct 2009 → Jul 2010 | Behcet disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 434 trials | ||||||
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07704190 | Jul 2026 → Dec 2028 expected | atherosclerotic cardiovascular disease, cardiovascular-kidney-metabolic syndrome, carotid stenosis, chronic kidney disease +4 | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07489573 | Jun 2026 → Sep 2029 expected | hidradenitis suppurativa | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 4 | NCT07149792 | Jul 2025 → Dec 2026 expected | psoriasis, psoriatic arthritis | Taichung Veterans General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06833112 | Feb 2025 → Aug 2027 expected | ankylosing spondylitis | The Affiliated Hospital Of Guizhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06398106 | Dec 2024 → Mar 2028 expected | psoriasis | University Hospital, Ghent | Recruiting | No outcome recorded |
| Phase 4 | NCT05303285 | Jun 2024 → Aug 2026 overdue | ankylosing spondylitis | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04239859 | Jan 2024 → Dec 2027 expected | psoriasis | Singapore General Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05622708 | Mar 2023 → Feb 2028 expected | spondyloarthropathy | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05527444 | Mar 2022 → Dec 2024 | ankylosing spondylitis | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT04535999 | Feb 2022 → May 2025 | psoriasis | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT05080218 | Nov 2021 → Apr 2024 | psoriatic arthritis, spondyloarthropathy | Jeffrey Curtis | Completed | No outcome recorded |
| Phase 4 | NCT05891964 | Jul 2021 → Jun 2022 | psoriasis | Jinnah Postgraduate Medical Centre | Completed | No outcome recorded |
| Phase 4 | NCT04717466 | Jun 2021 → May 2024 | psoriasis | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT04996485 | Mar 2021 → Mar 2023 | inherited ichthyosis | National Medical Research Center for Children's Health, Russian Federation | Unknown | No outcome recorded |
| Phase 4 | NCT04638647 | Dec 2020 → Jan 2030 expected | immune dysregulation, autoimmunity, and autoinflammation | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 4 | NCT04488185 | Nov 2020 → Mar 2021 | psoriasis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 4 | NCT04340076 | Aug 2020 → Jan 2025 | psoriasis | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04469829 | Aug 2020 → Dec 2021 | metabolic syndrome X, psoriasis | University of Verona | Unknown | No outcome recorded |
| Phase 4 | NCT03623867 | May 2020 → Sep 2022 | psoriatic arthritis | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT04571567 | Dec 2019 → Feb 2022 | psoriasis | Saakshi Khattri | Completed | No outcome recorded |
| Phase 4 | NCT04887597 | Mar 2019 → Mar 2022 | enthesitis, psoriatic arthritis | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 4 | NCT03639740 | Jan 2019 → Feb 2021 | ankylosing spondylitis | Professor Mikkel Østergaard | Unknown | No outcome recorded |
| Phase 4 | NCT03445845 | Dec 2018 → Sep 2024 | spondyloarthropathy | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 4 | NCT03440736 | Feb 2018 → Nov 2021 | metabolic syndrome X, psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT03307447 | Dec 2017 → Sep 2021 | psoriasis | Narrows Institute for Biomedical Research | Unknown | No outcome recorded |
| Phase 4 | NCT03055494 | Apr 2017 → Apr 2018 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT03020199 | Mar 2017 → Nov 2021 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT05676333 | Oct 2016 → Dec 2017 | vitiligo | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT02592018 | Oct 2016 → Dec 2018 | psoriasis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT02763046 | May 2016 → Sep 2019 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02752776 | Mar 2016 → Mar 2018 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02690701 | Feb 2016 → Apr 2017 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02547714 | Jun 2015 → May 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06707246 | Dec 2024 → Oct 2026 expected | hidradenitis suppurativa | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT05503875 | Jan 2023 → Dec 2027 expected | psoriasis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 28 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06126718 Comparator | Feb → Aug 2024 | psoriasis | BioRay Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07054970 Comparator | Jan → Aug 2024 | — | Celltrion | Completed | No outcome recorded |
| Phase 1 | NCT04711343 Comparator | Jun 2022 → May 2023 | psoriasis | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 1 | NCT04589026 Comparator | Oct 2020 → May 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01828086 Comparator | Jun 2013 → Oct 2015 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03384745 Comparator | Jul 2018 → Jun 2019 | psoriasis | Bond Avillion 2 Development LP | Completed | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT06945107 Comparator | May 2025 → Jun 2026 overdue | psoriasis | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06630559 Comparator | May 2025 → Feb 2026 overdue | psoriasis | Celltrion | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06398652 Comparator | Aug 2024 → Jun 2025 | psoriasis | Taizhou Mabtech Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT06110676 Comparator | Aug 2023 → Apr 2025 | psoriasis | Livzon Pharmaceutical Group Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT05377944 Comparator | Oct 2022 → May 2024 | psoriasis | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 3 | NCT04737330 Comparator | Nov 2021 → May 2023 | endocrine exophthalmos | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT04179175 Comparator | Mar 2020 → May 2023 overdue | hidradenitis suppurativa | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03713632 Comparator | Feb 2019 → Sep 2021 | hidradenitis suppurativa | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03713619 Comparator | Jan 2019 → Oct 2021 | hidradenitis suppurativa | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03535194 Comparator | Jun 2018 → Mar 2020 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT03536884 Comparator | Jun 2018 → Sep 2019 | psoriasis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03478787 Comparator | May 2018 → Jul 2020 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03090100 Comparator | Apr 2017 → Aug 2018 | psoriasis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02662985 Comparator | Aug 2016 → Nov 2020 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02474069 Comparator | Feb 2015 → Sep 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT07485764 Background | Jun 2026 overdue | obesity disorder, psoriasis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07261072 Comparator | Dec 2025 → Nov 2026 expected | hidradenitis suppurativa | Peking Union Medical College | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03350815 Comparator | Mar 2018 → Mar 2021 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02798211 Comparator | Jun 2016 → Dec 2018 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02144857 Comparator | May 2014 → Sep 2023 | psoriasis | University of Athens | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06729463 Comparator | Dec 2024 → Mar 2025 | psoriasis, psoriatic arthritis | South Valley University | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05583604 Background | — | hidradenitis suppurativa | Novartis Pharmaceuticals | Available | No outcome recorded |
Press releases naming this drug 85 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-03 | Novartis Pharmaceuticals | Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients novartis.com ↗ |
| 2026-03-13 | Novartis Pharmaceuticals | Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa novartis.com ↗ |
| 2025-10-22 | Novartis Pharmaceuticals | Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR) novartis.com ↗ |
| 2025-09-29 | Novartis Pharmaceuticals | Novartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US novartis.com ↗ |
| 2025-07-03 | Novartis Pharmaceuticals | Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA) novartis.com ↗ |
| 2023-10-31 | Novartis Pharmaceuticals | FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade novartis.com ↗ |
| 2023-06-01 | Novartis Pharmaceuticals | Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa novartis.com ↗ |
| 2023-04-26 | Novartis Pharmaceuticals | Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa novartis.com ↗ |
| 2023-02-04 | Novartis Pharmaceuticals | Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx® novartis.com ↗ |
| 2022-09-10 | Novartis Pharmaceuticals | Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials novartis.com ↗ |
| 2022-06-27 | Novartis Pharmaceuticals | Cosentyx® (secukinumab) receives expanded approvals in EU for use in childhood arthritic conditions novartis.com ↗ |
| 2022-05-20 | Novartis Pharmaceuticals | Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions novartis.com ↗ |
| 2021-12-23 | Novartis Pharmaceuticals | Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis novartis.com ↗ |
| 2021-11-08 | Novartis Pharmaceuticals | Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021 novartis.com ↗ |
| 2021-09-29 | Novartis Pharmaceuticals | New data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasis novartis.com ↗ |
| 2021-08-17 | Novartis Pharmaceuticals | Novartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis novartis.com ↗ |
| 2021-06-02 | Novartis Pharmaceuticals | Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021 novartis.com ↗ |
| 2021-06-01 | Novartis Pharmaceuticals | Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis novartis.com ↗ |
| 2021-02-26 | Novartis Pharmaceuticals | Novartis Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis novartis.com ↗ |
| 2020-11-05 | Novartis Pharmaceuticals | Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study novartis.com ↗ |
| 2020-10-29 | Novartis Pharmaceuticals | Novartis presents latest Phase III data reinforcing Cosentyx® as a first-line systemic treatment in pediatric psoriasis novartis.com ↗ |
| 2020-08-03 | Novartis Pharmaceuticals | Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis novartis.com ↗ |
| 2020-06-26 | Novartis Pharmaceuticals | Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile novartis.com ↗ |
| 2020-06-17 | Novartis Pharmaceuticals | Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis novartis.com ↗ |
| 2020-06-12 | AbbVie | AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks abbvie.com ↗ |
| 2020-06-04 | Novartis Pharmaceuticals | Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis novartis.com ↗ |
| 2020-04-29 | Novartis Pharmaceuticals | Novartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum novartis.com ↗ |
| 2020-03-27 | Novartis Pharmaceuticals | Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum novartis.com ↗ |
| 2020-01-31 | Novartis Pharmaceuticals | Novartis Cosentyx® builds on its axSpA leadership with US label update for dosing flexibility in ankylosing spondylitis novartis.com ↗ |
| 2020-01-14 | AbbVie | New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks abbvie.com ↗ |
| 2019-11-12 | Novartis Pharmaceuticals | New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis novartis.com ↗ |
| 2019-11-01 | Novartis Pharmaceuticals | Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis novartis.com ↗ |
| 2019-10-24 | Novartis Pharmaceuticals | Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis novartis.com ↗ |
| 2019-10-10 | Novartis Pharmaceuticals | Novartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis novartis.com ↗ |
| 2019-10-09 | Novartis Pharmaceuticals | Novartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx® in clinical practice novartis.com ↗ |
| 2019-10-02 | Novartis Pharmaceuticals | Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum novartis.com ↗ |
| 2019-09-17 | Novartis Pharmaceuticals | Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis novartis.com ↗ |
| 2019-06-26 | Novartis Pharmaceuticals | Novartis highlights new publication showing IL-17A antibody Cosentyx® improves inflammation and rapidly suppresses IL-23 in plaque psoriasis novartis.com ↗ |
| 2019-06-17 | Novartis Pharmaceuticals | New analysis of Novartis data confirms that Cosentyx® demonstrates durable comprehensive treatment across psoriatic disease novartis.com ↗ |
| 2019-06-12 | Novartis Pharmaceuticals | Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis novartis.com ↗ |
| 2019-06-12 | Novartis Pharmaceuticals | Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show novartis.com ↗ |
| 2019-04-02 | Novartis Pharmaceuticals | Novartis first-in-class Cosentyx® approved in China for psoriasis patients novartis.com ↗ |
| 2019-03-05 | Novartis Pharmaceuticals | Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®* novartis.com ↗ |
| 2019-03-04 | Novartis Pharmaceuticals | Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China novartis.com ↗ |
| 2018-10-26 | Novartis Pharmaceuticals | Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis novartis.com ↗ |
| 2018-10-16 | Novartis Pharmaceuticals | Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis novartis.com ↗ |
| 2018-09-13 | Novartis Pharmaceuticals | Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients novartis.com ↗ |
| 2018-06-13 | Novartis Pharmaceuticals | Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis novartis.com ↗ |
| 2018-05-15 | Novartis Pharmaceuticals | Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*) novartis.com ↗ |
| 2018-02-16 | Novartis Pharmaceuticals | Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis novartis.com ↗ |
| 2018-02-16 | Novartis Pharmaceuticals | Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis novartis.com ↗ |
| 2018-02-08 | Novartis Pharmaceuticals | Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis novartis.com ↗ |
| 2018-01-16 | Novartis Pharmaceuticals | Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients novartis.com ↗ |
| 2018-01-09 | Novartis Pharmaceuticals | Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab** novartis.com ↗ |
| 2017-11-30 | Novartis Pharmaceuticals | Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients novartis.com ↗ |
| 2017-11-07 | Novartis Pharmaceuticals | Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage novartis.com ↗ |
| 2017-11-06 | Novartis Pharmaceuticals | Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years novartis.com ↗ |
| 2017-10-30 | Novartis Pharmaceuticals | Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA novartis.com ↗ |
| 2017-09-13 | Novartis Pharmaceuticals | Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data novartis.com ↗ |
| 2017-07-14 | Novartis Pharmaceuticals | Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis novartis.com ↗ |
| 2017-07-06 | Novartis Pharmaceuticals | Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis novartis.com ↗ |
| 2017-06-15 | Novartis Pharmaceuticals | Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years novartis.com ↗ |
| 2017-04-25 | Novartis Pharmaceuticals | Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued novartis.com ↗ |
| 2017-03-21 | Novartis Pharmaceuticals | Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis novartis.com ↗ |
| 2017-03-06 | Novartis Pharmaceuticals | Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause novartis.com ↗ |
| 2016-11-14 | Novartis Pharmaceuticals | Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain novartis.com ↗ |
| 2016-10-31 | Novartis Pharmaceuticals | Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product novartis.com ↗ |
| 2016-10-01 | Novartis Pharmaceuticals | Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients novartis.com ↗ |
| 2016-06-08 | Novartis Pharmaceuticals | Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 novartis.com ↗ |
| 2016-03-05 | Novartis Pharmaceuticals | Novartis' Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks novartis.com ↗ |
| 2016-01-15 | Novartis Pharmaceuticals | Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US novartis.com ↗ |
| 2015-12-23 | Novartis Pharmaceuticals | Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients novartis.com ↗ |
| 2015-11-23 | Novartis Pharmaceuticals | Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis novartis.com ↗ |
| 2015-11-08 | Novartis Pharmaceuticals | Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients novartis.com ↗ |
| 2015-11-08 | Novartis Pharmaceuticals | New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis novartis.com ↗ |
| 2015-10-23 | Novartis Pharmaceuticals | Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis novartis.com ↗ |
| 2015-10-10 | Novartis Pharmaceuticals | Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 years novartis.com ↗ |
| 2015-09-30 | Novartis Pharmaceuticals | Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis novartis.com ↗ |
| 2015-06-29 | Novartis Pharmaceuticals | Novartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patients novartis.com ↗ |
| 2015-06-11 | Novartis Pharmaceuticals | Novartis presents new data at WCD demonstrating significant efficacy of Cosentyx® in patients with psoriasis of the nails, palms and soles novartis.com ↗ |
| 2015-06-10 | Novartis Pharmaceuticals | Novartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing spondylitis patients novartis.com ↗ |
| 2015-03-21 | Novartis Pharmaceuticals | Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients novartis.com ↗ |
| 2015-03-20 | Novartis Pharmaceuticals | New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients novartis.com ↗ |
| 2015-01-21 | Novartis Pharmaceuticals | Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients novartis.com ↗ |
| 2015-01-19 | Novartis Pharmaceuticals | Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients novartis.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 205 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Secukinumab | “A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous...” NCT00928512 ↗160“To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis.” PMID 23290985 ↗ Jan 2013 “This withdrawn study was to assess the safety and efficacy of secukinumab compared to etanercept and placebo in patients who have moderate to severe, chronic, plaque-type psoriasis.” NCT01900782 ↗ “This study will characterize the pharmacokinetic, safety and immunogenicity of BR201 versus Cosentyx（Secukinumab ） in healthy male subjects after a single dose.” NCT06126718 ↗ “The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease.” PMID 22595313 ↗ May 2012 “CT-P55, containing the active ingredient secukinumab, is being developed by CELLTRION, Inc. as a proposed biosimilar to the reference product, Cosentyx.” NCT07054970 ↗ “Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis” NCT01874340 ↗ “Secukinumab (Cosentyx)” NCT07149792 ↗ |
| Known as | AIN457 | “This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks...” NCT07489573 ↗50“Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)” NCT01392326 ↗ “Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).” NCT01952015 ↗ “Open-label Secukinumab PFS (prefilled syringe) will be labeled as AIN457 150mg/1mL” NCT05622708 ↗ “with Secukinumab (AIN457) as a First-line Biologic” NCT03906136 ↗ “secukinumab (AIN457) 150mg or 300mg subcutaneous” NCT01365455 ↗ “secukinumab (AIN457) 150mg or 300mg subcutaneous” NCT01358578 ↗ “AIN 457 core study /AIN 457 Extension” NCT01433250 ↗ “Secukinumab (AIN457) 150 mg s.c.” NCT01989468 ↗ “Secukinumab (AIN457) 150 mg s.c.” NCT02763046 ↗ “Drug: Secukinumab (AIN457)” NCT02547714 ↗ “Secukinumab (AIN457)” NCT01961609 ↗ “Secukinumab (AIN457)” NCT01770379 ↗ “Secukinumab (AIN457)” NCT01544595 ↗ “secukinumab (AIN457)” NCT01539213 ↗ “AIN457 (secukinumab)” NCT01478360 ↗ “secukinumab (AIN457)” NCT01359943 ↗ “Drug: AIN 457” NCT00685399 ↗ |
| Known as | AIN457A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01169844 ↗ |
| Known as | CMAB015 | “new process CMAB015（Secukinumab ） 150 mg Subcutaneous injection in upper arm” NCT07254325 ↗ |
| Known as | COSENTYX | “CT-P55, containing the active ingredient secukinumab, is being developed by CELLTRION, Inc. as a proposed biosimilar to the reference product, Cosentyx.” NCT07054970 ↗17“administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma” NCT07237594 ↗ “Combining Cosentyx (Secukinumab) (4-weekly, 300 mg s.c.) With a Lifestyle Intervention to Cosentyx Therapy Alone” NCT03440736 ↗ “About 20 patients suffering from severe psoriasis will take Cosentyx vials by intravenous infusion as :” NCT06729463 ↗ “the reference product secukinumab (Cosentyx®) in healthy Chinese male subjects” PMID 39224901 ↗ Aug 2024 “Cosentyx（Secukinumab ） 150 mg Subcutaneous injection in upper arm” NCT07254325 ↗ “Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]” NCT04403243 ↗ “Secukinumab 150 milligram [Cosentyx]” NCT03639740 ↗ “Secukinumab Auto-Injector [Cosentyx]” NCT04414605 ↗ “Secukinumab (Cosentyx)” NCT07149792 ↗ |
| Known as | Cosentyx TM | “"Secukinumab" "Cosentyx TM" 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.” NCT02795416 ↗ |
| Known as | Secukinumab (AIN457) 150 mg s.c. | “Secukinumab (AIN457) 150 mg s.c.” NCT02159053 ↗ |
| Action | Inhibit | “Anti IL-17 Monoclonal Antibody” NCT00584740 ↗ |
| Modality | Monoclonal antibody | “Anti IL-17 Monoclonal Antibody” NCT00584740 ↗ |
| Route | Intravenous | “AIN457 10 mg/kg was given as an intravenous infusion at day 1 and day 22.” NCT00584740 ↗ |
| Target | IL17A | “a human antibody to IL-17A” PMID 20926833 ↗ Oct 2010 |